Is biopharma’s first $1.5M therapy now in Phase III?
Keying off of Spark Therapeutics’ rollout of Luxturna as the first approved gene therapy in the US, the analysts at Leerink have been crunching the numbers on what the first hemophilia gene therapies could fetch. And by raising their estimate to $1.5 million, they may well be tempting fate at a time the debate over drug pricing is reaching the boiling point in the US.
Spark satisfied most analysts with its $425,000 price per eye for Luxturna. And Leerink says that the positive response by Harvard Pilgrim to a 30-month durability starting point for a gene therapy pricing agreement set the stage for many of the rest of the field to follow suit. And that will justify a $1.5 million-plus price for a therapy that could replace current standards in hemophilia with a similar track record on durability.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.